321 related articles for article (PubMed ID: 28064383)
21. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
[TBL] [Abstract][Full Text] [Related]
22. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
Kim HS; Umbricht CB; Illei PB; Cimino-Mathews A; Cho S; Chowdhury N; Figueroa-Magalhaes MC; Pesce C; Jeter SC; Mylander C; Rosman M; Tafra L; Turner BM; Hicks DG; Jensen TA; Miller DV; Armstrong DK; Connolly RM; Fetting JH; Miller RS; Park BH; Stearns V; Visvanathan K; Wolff AC; Cope L
J Clin Oncol; 2016 Dec; 34(36):4390-4397. PubMed ID: 27998227
[TBL] [Abstract][Full Text] [Related]
24. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
25. Applying new Magee equations for predicting the Oncotype Dx recurrence score.
Sughayer M; Alaaraj R; Alsughayer A
Breast Cancer; 2018 Sep; 25(5):597-604. PubMed ID: 29691722
[TBL] [Abstract][Full Text] [Related]
26. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
Auerbach J; Kim M; Fineberg S
Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
[TBL] [Abstract][Full Text] [Related]
27. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX
Turner BM; Finkelman BS; Hicks DG; Numbereye N; Moisini I; Dhakal A; Skinner K; Sanders MAG; Wang X; Shayne M; Schiffhauer L; Katerji H; Zhang H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765860
[TBL] [Abstract][Full Text] [Related]
28. Benefits of introduction of Oncotype DX
Green N; Al-Allak A; Fowler C
Ann R Coll Surg Engl; 2019 Jan; 101(1):55-59. PubMed ID: 30322288
[TBL] [Abstract][Full Text] [Related]
29. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Carlson JJ; Roth JA
Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
[TBL] [Abstract][Full Text] [Related]
30. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
[TBL] [Abstract][Full Text] [Related]
31. Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings.
Li H; Whitney J; Bera K; Gilmore H; Thorat MA; Badve S; Madabhushi A
Breast Cancer Res; 2019 Oct; 21(1):114. PubMed ID: 31623652
[TBL] [Abstract][Full Text] [Related]
32. Pathologist's health-care value in the triage of Oncotype DX
Dabbs DJ; Clark BZ; Serdy K; Onisko A; Brufsky AM; Smalley S; Perkins S; Bhargava R
Histopathology; 2018 Oct; 73(4):692-700. PubMed ID: 29920746
[TBL] [Abstract][Full Text] [Related]
33. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
34. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Karsten M; Stempel M; Radosa J; Patil S; King TA
Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
[TBL] [Abstract][Full Text] [Related]
35. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY; Chen T; Dang W; Mougalian SS; Evans SB; Gross CP
J Natl Compr Canc Netw; 2019 Jan; 17(1):39-46. PubMed ID: 30659128
[No Abstract] [Full Text] [Related]
36. Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?
Kapadia S; Gudiwada SP; Kaji AH; Chlebowski RT; Venegas R; Ozao-Choy J; Dauphine C
Breast J; 2020 Nov; 26(11):2199-2202. PubMed ID: 33001531
[TBL] [Abstract][Full Text] [Related]
37. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
Klein ME; Dabbs DJ; Shuai Y; Brufsky AM; Jankowitz R; Puhalla SL; Bhargava R
Mod Pathol; 2013 May; 26(5):658-64. PubMed ID: 23503643
[TBL] [Abstract][Full Text] [Related]
38. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
[No Abstract] [Full Text] [Related]
39. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
[TBL] [Abstract][Full Text] [Related]
40. A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning.
Kim I; Choi HJ; Ryu JM; Lee SK; Yu JH; Kim SW; Nam SJ; Lee JE
Eur J Surg Oncol; 2019 Feb; 45(2):134-140. PubMed ID: 30348602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
